Efficacy, safety, and quality-of-life of treatments for acute relapses of multiple sclerosis: results from a literature review of randomized controlled trials.
Jessica CostelloAnnete NjueMatthew LyallAnne HeyesNancy MahlerMichael PhilbinTara NazarethPublished in: Degenerative neurological and neuromuscular disease (2019)
RCTs indicate IVMP and RCI are efficacious and well tolerated treatments for MS relapse. Overall, many RCTs were dated, with sample sizes of fewer than 30 patients and no definitions for relapse nor clinically significant change. Contemporary evidence generation for all relapse treatments of interest, across efficacy, safety, and QOL outcomes, is still needed.
Keyphrases
- multiple sclerosis
- end stage renal disease
- free survival
- ejection fraction
- newly diagnosed
- chronic kidney disease
- liver failure
- peritoneal dialysis
- prognostic factors
- intensive care unit
- ms ms
- type diabetes
- respiratory failure
- metabolic syndrome
- patient reported outcomes
- weight loss
- hepatitis b virus
- glycemic control
- patient reported
- insulin resistance